Monk on KEYNOTE-A18 Data of Pembro/Chemoradiotherapy in Cervical Cancer
November 15th 2023Bradley J. Monk, MD, FACS, FACOG, discusses the phase 3 KEYNOTE-A18 study of pembrolizumab with chemoradiotherapy for the treatment of patients with newly diagnosed, previously untreated, high-risk locally advanced cervical cancer.
Key Takeaways from the OUTBACK Trial of Adjuvant Chemotherapy in Cervical Cancer
July 23rd 2022Bradley Monk, MD, FACCOG, FACS, discusses main takeaways from the OUTBACK trial of adjuvant chemotherapy following chemoradiation as primary treatment in patients with locally advanced cervical cancer vs chemoradiation alone.